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Abstract
Immunodeficiency, Centromeric Instability, Facial Anomalies (ICF) syndrome is a rare autosomal recessive disorder that is
characterized by a marked immunodeficiency, severe hypomethylation of the classical satellites 2 and 3 associated with
disruption of constitutive heterochromatin, and facial anomalies. Sixty percent of ICF patients have mutations in the
DNMT3B (DNA methyltransferase 3B) gene, encoding a de novo DNA methyltransferase. In the present study, we have
shown that, in ICF lymphoblasts and peripheral blood, juxtacentromeric heterochromatic genes undergo dramatic changes
in DNA methylation, indicating that they are bona fide targets of the DNMT3B protein. DNA methylation in heterochromatic
genes dropped from about 80% in normal cells to approximately 30% in ICF cells. Hypomethylation was observed in five ICF
patients and was associated with activation of these silent genes. Although DNA hypomethylation occurred in all the
analyzed heterochromatic genes and in all the ICF patients, gene expression was restricted to some genes, every patient
having his own group of activated genes. Histone modifications were preserved in ICF patients. Heterochromatic genes
were associated with histone modifications that are typical of inactive chromatin: they had low acetylation on H3 and H4
histones and were slightly enriched in H3K9Me3, both in ICF and controls. This was also the case for those heterochromatic
genes that escaped silencing. This finding suggests that gene activation was not generalized to all the cells, but rather was
restricted to a clonal cell population that may contribute to the phenotypic variability observed in ICF syndrome. A slight
increase in H3K27 monomethylation was observed both in heterochromatin and active euchromatin in ICF patients;
however, no correlation between this modification and activation of heterochromatic genes was found.
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Introduction
ICF (Immunodeficiency, Centromeric Instability, and Facial
Anomalies; OMIM #242860), is a rare autosomal recessive
disorder. Up to now, less than fifty cases have been reported. Most
of the ICF patients were born from consanguineous marriages and
about 60% had mutations in the DNMT3B (DNA methyltransferase
3B) gene that maps to the 20q11.2 region [1–3]. The DNMT3B
enzyme catalytically methylates cytosines in CpG pairs, which are
later bound by repressor complexes.
Several mutations have been described in ICF syndrome, most
of them (79%) lying in the gene portion encoding the C-terminal
catalytic domain. These mutations induce a decrease of the
enzymatic activity. The less frequent N-terminal mutations are
mostly nonsense mutations that arise as compound heterozygous
mutations. Forty percent of clinically diagnosed ICF patients do
not carry any mutation of this gene, suggesting mutational
heterogeneity or involvement of other genes. Consequently, it
has been postulated that there are two types of ICF patients: type 1
patients bearing mutations in the DNMT3B gene and type 2
patients without known mutations [4]. In murine models,
mutations in the Dnmt3b gene negatively affect proper embryonic
development [2,5].
ICF syndrome is characterized by a marked immunodeficiency:
patients tend to have low levels of immunoglobulins and may
exhibit low levels of B and T cells. The B cell defects associated
with agammaglobulinemia or hypogammaglobulinemia in ICF
type 1 are characterized by only naı ¨ve and no memory B cells in
peripheral blood (PB) [6]. Negative selection is impaired and
newly generated and immature B cells accumulate in PB due to B
cell maturation blockage. Because of chronic respiratory and
gastrointestinal infections, many patients die at an early age. Facial
anomalies are a heterogeneous trait in ICF syndrome and mainly
include hypertelorism, epicanthal folds, abnormally low-set ears,
and macroglossia. Stature is often reduced. Centromeric instability
is the most typical feature of the disease. The juxtacentromeric
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undercondensed and is involved in chromosome rearrangements
and multiradiate associations. The instability correlates with a
severe hypomethylation of the classical satellites 2 and 3, which are
the major components of constitutive heterochromatin. ICF
syndrome was the first genetic disease to be associated with a
constitutional methylation defect, mainly affecting heterochroma-
tin. The methylation anomalies of ICF syndrome can involve
other genomic sequences such as a satellites, the centromeric
component of constitutive heterochromatin [7], Alu sequences [8],
D4Z4 and NBL2 repeats [9], and imprinted genes [3,10].
Since it was rather unlikely that hypomethylation of non-
coding repetitive sequences accounted for the severe clinical
features that characterize ICF patients, several attempts were
made in the past to search for genes that lost DNA methylation
and, subsequently, became transcriptionally active in these
patients. Hansen et al. [10] analyzed eleven genes that are
normally subject to X inactivation, including SYBL1, that is also
present in chromosome Y. In ICF patients, the inactive alleles of
these genes were hypomethylated and some of them escaped
silencing. Escape from silencing in ICF cells was associated with a
marked advance in replication timing from a late to an active X-
like pattern [10]. More recently, ICF-specific changes in RNA
levels of genes critical for immune function, development, and
neurogenesis were identified through the analysis of global
expression profiles [11–13]. These studies showed that changes
in gene expression occurred across the whole genome and in both
directions (under- and overexpression) in ICF compared to
control lymphoblast cells. In two of these studies, DNA
methylation did not change in differently expressed genes
[11,13]; the third study identified subtle but significant changes
[12].
In previous reports, we showed that in tumor cells and cancer
cell lines juxtacentromeric genes became hypomethylated and
escaped silencing [14,15]. Hypomethylation was very striking
(DNA methylation dropped from 80% to less than 40%) and also
frequent. In this work, we investigated whether heterochromatic
genes escape silencing in ICF cells too.
Results
Patient description
Table 1 lists patients and controls analyzed in this study. Four
patients (ICF1, ICF2, ICF4, and ICF5) had ICF-specific clinical
and karyotypic features. Among them two patients had previously
described mutations in the DNMT3B gene (type 1 patients) and
two siblings had no mutations in the DNMT3B gene (type 2
patients). Patient ICF3 presented the cytogenetic rearrangements
that are commonly associated with ICF syndrome (chromosome
breakages and multiradial configurations); however, he did not
suffer from immunodeficiency and had no facial anomalies.
Genomic sequencing showed this patient had a missense
mutation (K770E) in the DNMT3B gene that had never been
described before. He was homozygous for this mutation, his
parents, who were first cousins, being heterozygous. The missense
mutation resulted in an aminoacid change in the catalytic
domain. This amino acid is phylogenetically conserved in various
animal species.
Heterochromatic genes were hypomethylated in ICF cells
A large majority of juxtacentromeric regions have been left out
from the genome sequencing project as segmental duplications
made clone assembly and sequencing troublesome in these
chromosome regions. Thus, to determine whether juxtacentro-
meric heterochromatic genes were hypomethylated in ICF
patients, we chose chromosome 21 for which well annotated
sequences bridging the chromosome arms with centromeric and
juxtacentromeric satellites are available [15–17]. A physical map
of the 2.3-Mb region that was analyzed in this work is provided in
Fig. 1a. Using the CpG island searcher program [18], we scanned
the genomic sequence of human chromosome 21 [17] and
searched for CpG islands that were associated with the 5’ region
of the genes. We analyzed DNA methylation in seven genes
mapping to the juxtacentromeric region of human chromosome
21. Three genes (TPTE, BAGE2,a n dPOTED) mapped to the
duplication-rich heterochromatic domain and four genes
(RBM11, ABCC13, STCH, and NRIP1) mapped to the duplica-
tion-free euchromatic domain [15,16]. Two euchromatic genes
LIPI and SAMSN1 were excluded from the methylation analysis
because the former gene shared a CpG island with RBM11 (the
two genes are head-to-head with the CpG island in the middle)
and the latter gene had no associated CpG island. For each gene,
we chose a set of nested primers allowing us to amplify a 500-bp
DNA stretch in the 5’ CpG island and we analyzed DNA
methylation by bisulphite and genomic sequencing in ICF
patients and in controls. An example of methylation patterns is
shown in Fig. 1d. Since heterochromatic genes belonged to
families comprising several loci that have .90% nucleotide
sequence identity [16], we selected primers that specifically
amplified the gene copy located in chromosome 21. Primer
specificity was checked using DNA from a monochromosome
hybrid panel. Heterochromatic genes were hypermethylated in
controls and hypomethylated in ICF patients (Fig. 1 and Table 2).
Hypomethylation was striking (DNA methylation dropped from
about 80% in normal cells to approximately 30% in ICF cells)
and frequent (present in five analyzed patients). Interestingly,
BAGE2 was hypomethylated only in type 2 patients (x
2 test, p-
value ,0.001). DNA methylation of BAGE genes was also
Table 1. List of patients and controls.
DNMT3B
Mutations(b) sex age (years) cells (c)
N1 - F 28 PB
N2 - M 36 PB
N3 - F 43 PB
N4 - M 46 PB
N5 - M 17 PB
N6 - M 15 PB
N7 - F 37 PB
N8 - M 41 PB
N9 - M 7 LB
N10 - F 3 LB
N11 - M 30 LB
ICF1 (a) - M 15 LB, PB
ICF2 (a) - M 14 LB
ICF3 K770E M 13 LB, PB
ICF4 D817G F 1 LB, PB
ICF5 A603T/STP807ins F 1 LB
N = controls.
(a) brothers.
(b) codon numbers refer to splice isoform GenBank accession no AF156488.
(c) PB, peripheral blood; LB, lymphoblast cells.
doi:10.1371/journal.pone.0019464.t001
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case, we measured the global methylation of twelve BAGE loci
mapped to the juxtacentromeric regions of chromosomes 9, 13,
18, and 21 [19,20]. BAGE loci were hypomethylated in all the
ICF patients, regardless of the type, and were hypermethylated in
controls. This finding shows that loss of DNA methylation is not
restricted to the juxtacentromeric region of chromosome 21, but
is common to other chromosomes.
Genes located in the euchromatic duplication-free domain were
hypomethylated both in ICF patients and controls. One exception
was represented by the ABCC13 gene, which was slightly
methylated in controls (35.2% 5mCpG) and significantly hypo-
methylated in ICF patients (17.5% 5mCpG) (x
2test, p-value
,0.001).
To achieve our analysis, we analyzed DNA methylation of
satellite 2 using the bisulphite and genomic sequencing method.
Satellite 2 was much less methylated in ICF patients than in
controls (x
2test, p-value ,0.001) (Fig. 1c).
In patient ICF3, satellite 2 was as methylated as in controls; in
contrast, two heterochromatic genes (TPTE and POTED) and the
normally methylated euchromatic gene ABCC13 had a significant,
but less striking loss of DNA methylation compared to the other
patients (Table 2).
Heterochromatic genes escaped silencing in ICF cells
Afterwards, we decided to investigate whether DNA hypomethy-
lationwasassociated withtheactivation ofheterochromaticgenesin
ICF patients. Gene expression was first analyzed by reverse
transcription and standard PCR on total RNA in five ICF patients
and eleven controls. Either TPTE, or POTE, or both genes were
expressed in four ICF patients, but were silent in controls. No
heterochromatic genes were expressed by patient ICF3. The BAGE
genes were expressed neither in ICF patients nor in controls. The
expression levels of TPTE and POTE, which were specifically
activated in ICF cells, was measured by real-time PCR (Fig. 2). The
level of expression of TPTE was correlated with the degree of
hypomethylation (Fig. 2a). Primers used for the expression analysis
of heterochromatic genes were not specific for the gene copies
located on chromosome 21. Thus, to determine which POTE and
which TPTE were expressed by the ICF cells, we cloned and
sequenced the RT-PCR products. The ICF cells expressed POTEF
from chromosome 2, POTEG from chromosome 14, but they did
not express POTED from chromosome 21. ICF patients also
expressed TPTE from chromosome 21 and TPTE2 from chromo-
some 13[21]. Overall, every patient had his own group of activated
genes and activation of heterochromatic genes was not restricted to
chromosome 21, but occurred in several chromosomes (Table 3).
Figure 1. Heterochromatic genes and satellite 2 are hypomethylated in ICF patients. a) Physical map of the 2.3-Mb juxtacentromeric
region of human chromosome 21 analyzed in this study. The centromere (cen) is not shown to scale. Genes are bold typed; truncated genes are
indicated by plain text and retrotransposed pseudogenes are italicized. b) Histograms represent the percentages of DNA methylation in the analyzed
genes either in a pool of controls (black bars) or in a pool of ICF patients (white bars). c) DNA methylation in satellite 2. d) DNA methylation pattern of
TPTE, a heterochromatic gene, in a control (left) and an ICF patient (right): full circles are 5mCpG and hollow circles are unmethylated CpG.
doi:10.1371/journal.pone.0019464.g001
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same expression pattern in ICF patients as in controls: SAMSN-1
and STCH were strongly expressed, NRIP1 was weakly expressed,
and LIPI, RBM11, and ABCC13 were silent.
Activation of heterochromatic genes was not associated
with chromatin changes in ICF cells
Histone modifications were analyzed in three ICF (ICF3, ICF4,
and ICF5) and three control (N9, N10, and N11) lymphoblast cell
lines. Two patients (ICF1 and ICF2) could not be analyzed,
because their cell lines were lost during the course of this project.
ChIP (Chromatin Immunoprecipitation) experiments were done
using antibodies against four histone isoforms (H3K9Me3,
H3K27Me, H3K9Ac, and H4Ac) (Fig. 3).
Active and silent heterochromatic genes had similar histone
modifications. We analyzed TPTE and TPTE2, but not POTE
genes. In this gene family, given the presence of thirteen copies
dispersed on eight chromosomes [22], we failed to design
chromosome-specific primers for real-time PCR.
Then, we compared histone modifications in ICF patients
versus controls in the whole set of juxtacentromeric genes. Histone
acetylation and H3K9 trimethylation were similar in ICF patients
and in controls; in contrast, monomethylation of H3K27 in three
genes (TPTE, TPTE2 and STCH) was significantly higher in ICF
patients than in controls.
Finally, we analyzed histone modifications in the three
chromatin domains that are present in the juxtacentromeric
region of human chromosome 21: heterochromatin, active
euchromatin and silent euchromatin. The heterochromatic genes
TPTE and TPTE2 were characterized by very low levels of
acetylation both in H4 and in H3K9 histones and had
monomethylation of H3K27 and trimethylation of H3K9. In the
euchromatic domain, histone modifications correlated with gene
expression. STCH and SAMSN-1, which were highly expressed,
were highly acetylated and had low levels of H3K9Me3. STCH
was also highly enriched in H3K27Me. ABCC13, RBM11 and
NRIP1, three euchromatic genes that were either silent or very
weakly expressed, were characterized by very low levels of
acetylation and were slightly enriched in H3K9Me3. In silent
euchromatic genes, H3K27Me was very low.
Table 2. DNA methylation (%).
Controls ICF
Type 1 Type 2
N9 N10 N2 N6 N7 N4 Total ICF5 ICF4 ICF3 ICF1 ICF2 Total p-value
Heterochromatin
Satellite 2 73.3 71.8 95.2 89.0 81.5 19.1 20.2 69.2 12.9 20.9 27.9 ,0.001
TPTE 76.7 64.3 65.8 65.5 62.0 80.8 68.9 11.6 4.7 41.1 38.9 27.3 21.4 ,0.001
BAGE2 80.0 75.4 91.7 96.0 84.8 73.2 81.3 83.6 14.9 0 80.3 n.s. Type1
8.9 ,0.001 Type2
POTED 81.0 82.9 83.3 82.1 82.4 41.2 26.1 66.3 30.0 55.5 42.6 ,0.001
Euchromatin
RBM11 1.3 1.0 2.9 0.5 1.5 2.2 0.4 2.0 0.6 0 1.1 n.s.
ABCC13 36.4 33.3 35.8 35.4 35.2 21.6 23.4 25.3 14.4 12.2 19.3 ,0.001
STCH 0.7 1.5 0 0 0.7 0.4 0.5 0.5 0 0.4 0.4 n.s.
NRIP1 0.3 2 0 0.7 0 1.7 0.7 1.7 0 0.8 n.s.
n.s., not significant.
doi:10.1371/journal.pone.0019464.t002
Figure 2. Heterochromatic genes escape silencing in ICF
patients. Black bars represent gene expression of two heterochromatic
gene families that were expressed in ICF patients: TPTE (a) and POTE (b).
The ABL gene was used to normalize cDNA amounts. I, ICF patients; N,
controls. Type 1, 2 are ICF patients with and without known mutations
in the DNMT3B gene, respectively. For TPTE (a) we superposed the
percentage of DNA methylation (white bars).
doi:10.1371/journal.pone.0019464.g002
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Juxtacentromeric heterochromatic genes lose DNA
methylation and escape silencing in ICF cells, without
apparent chromatin changes
In the present study, we have shown that juxtacentromeric
heterochromatic genes lost DNA methylation and escaped silencing
in ICF cells. Such a finding was not emphasized by previous
cytogenetic analyses of constitutive heterochromatin that detected
hypomethylation and chromatin decondensation only in the satellite-
rich domains. We analyzed chromosome 21 for which genomic
sequences bridging the chromosome arms with centromeric and
juxtacentromeric satellites are available [16–17]. However, having
looked at paralogous genes scattered in various chromosomes, we
showed that loss of methylation in juxtacentromeric heterochromatic
genes occurred in many chromosomes. Hypomethylation was
observed both in type 1 and type 2 patients. Only BAGE2 was
specifically hypomethylated in type 2 ICF patients. A similar finding
was reported for a satellite sequences whose hypomethylation was
also restricted to type 2 patients [4]. Alpha satellite sequences are
located within centromeres and BAGE2 maps very close to the
beginning of a satellite sequences [16]. Centromeric chromatin is
structurally and functionally distinct from the flanking juxtacentro-
meric heterochromatin: it contains blocks of histone H3 nucleosomes
interspersed with blocks of CENP-A (an H3 variant) nucleosomes
[23]. Centromeric chromatin is also characterized by a pattern of
histone modifications that is different from that of the flanking
heterochromatin [23]. So, it is tempting to suggest that loss of DNA
methylation in ICF patients of type 2 might resultfrom impairment of
one of the proteins responsible for the centromeric epigenetic pattern.
Interestingly, CENP-C, one of the proteins contributing to
centromeric chromatin organization, interacts with DNMT3B and
modulates DNA methylation both in centromeric and juxtacentro-
meric regions [24].
Table 3. Heterochromatic genes activated in ICF cells.
ICF1 TPTE2
ICF2 TPTE2 POTEG
ICF4 TPTE POTEF
ICF5 TPTE TPTE2 POTEF
doi:10.1371/journal.pone.0019464.t003
Figure 3. Relative enrichment of histone modifications in expressed euchromatic (E+), silent euchromatic (E–), and heterochromatic
(H) genes. Symbols represent single experiments either in an ICF (diamond) or in a control (circle) cell line. Filled markers denote expressed genes.
The significance of the differences between ICF patients and controls was evaluated for each modification and for each gene using Wilcoxon’s rank
sum test (p).
doi:10.1371/journal.pone.0019464.g003
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controls, with the exception of ABCC13. In normal cells, this gene
was slightly methylated, but less than the heterochromatic genes.
The presence of methylation in ABCC13 is consistent with the
notion that it is undergoing a pseudogenization process [16].
ABCC13 was significantly hypomethylated in ICF cells, showing
that hypomethylation occurs also in the euchromatic domain that
flanks the constitutive heterochromatin, but is much less striking.
In four ICF patients, heterochromatic genes escaped silencing.
Transcription was detected in various paralogs, suggesting that,
similar to DNA hypomethylation, gene activation was not
restricted to chromosome 21, but occurred in several chromo-
somes.
Although DNA hypomethylation was generalized to all the
heterochromatic genes and to all ICF patients, gene expression
was restricted to some genes and every patient had his own group
of activated genes. The activated genes differed even in two
brothers (ICF1 and ICF2). This finding is consistent with what we
previously observed in cancer, where heterochromatic genes
became hypomethylated in almost all the tumors, but were
expressed only in some of them and every tumor had a specific set
of activated genes [14]. The precise mechanism driving transcrip-
tion of heterochromatic genes in ICF cells is unknown. Clearly,
impairment of DNMT3B results in hypomethylation that,
however, is not sufficient to allow transcription. Other epigenetic
changes might occur, i.e. at the chromatin level. Thus, to better
understand gene regulation in human heterochromatic regions, we
next analyzed histone modifications by ChIP. Genes located in the
euchromatic flanking domain had either active or repressive
histone modifications, depending on their expression status.
Heterochromatic genes, on the contrary, were associated with
histone modifications that were typical of inactive chromatin: they
were hypoacetylated and slightly enriched in H3K9Me3 and
H3K27Me. This was also the case for expressed heterochromatic
genes. Since it is unlikely that hypoacetylated genes are
transcribed, we suggest that in ICF cells, gene activation is not
generalized to all the cells, but rather is restricted to a small
percentage of them. Clonal changes in chromatin may result from
epigenetic modifications occurring during lymphocyte differenti-
ation. If few cells express heterochromatic genes, transcripts can be
detected by RT-PCR; on the other hand, if chromatin changes
occur stochastically in a small percentage of cells, ChIP analysis on
the whole cell population will not detect them. DNA hypomethy-
lation, in contrast, occurred in all the cells, as the bisulphite and
sequencing patterns of different colonies from a same tissue were
rather homogeneous (Fig. 1d). It is likely that similar events take
place in the inactive X chromosome of ICF cells, where genes
subject to inactivation are hypomethylated, escape silencing, but
exhibit normal histone modification patterns [25]. Finally, in ICF
cells, hypomethylation of subtelomeric regions was associated with
aberrant transcription of these sequences, but no information on
the chromatin structure was provided [26]. Previous genome-wide
transcriptomic analyses identified more than 700 differently
expressed genes in ICF patients; however, none of them identified
aberrant expression of these heterochromatic genes [12,13]. One
possible explanation is that these previous studies focused on genes
expected to be relevant for ICF phenotype, whereas we analyzed
specifically heterochromatic genes. In addition, Jin et al. [12]
selected genes that had a high expression variability between ICF
and controls, but not within these two groups of individuals. Yet,
the aberrant expression of heterochromatic genes is highly variable
within ICF patients. Ehrlich et al. [13] did not observe significant
changes in differently expressed genes, whereas Jin et al. [12]
reported significant, but subtle DNA methylation differences in
approximately half the analyzed upregulated genes. Our work
shows that heterochromatic genes undergo dramatic changes in
DNA methylation, indicating that they are bona fide targets of the
DNMT3B protein.
H3K27 monomethylation is increased in ICF lymphoblast
cell lines
Much less characterized than trimethylation, monomethylation
of H3K27 was first described as a repressive mark that is
preferentially localized in heterochromatin, but is also found in
euchromatic regions [27]. Recent genome-wide analyses have
shown that this mark is frequently associated with the promoter of
active genes [28]. Our results are consistent with both statements,
as we found H3K27 monomethylation in heterochromatin and in
active euchromatin, but not in silent euchromatin. Interestingly,
H3K27 monomethylation was higher in ICF lymphoblasts than in
controls. More patients should be analyzed to corroborate these
data. Alteration of this histone mark may be relevant to ICF
syndrome, as H3K27 methylation plays an important role during
the development of the B lymphoid lineage [29] and ICF patients
have immature B cells in the blood [6].
Aberrant transcription of heterochromatic genes and ICF
syndrome
A common feature of heterochromatic genes is their expression
pattern mostly restricted to germ cells. TPTE and TPTE2 genes are
strongly expressed in testis, in secondary spermatocytes and/or very
early spermatids [30]. POTE genes are expressed in a few normal
tissues (namely testis, prostate, ovary and placenta), in embryonic
stem cell lines, and in various cancers [31,32]. Immunochemistry
showed that POTE proteins localized in primary spermatocytes in
the seminiferous tubules [33]. The high expression of POTE in
spermatocytes suggests a role in spermatogenesis. Finally, BAGE
genes are exclusively expressed in cancer and testis, encode small
putative proteins that have no homology to known domains, and
have no orthologs in other mammalian species [19,20]. Very
interestingly, in hypomorphic Dnm3b mutant mice, genes that are
normally expressed in testis are aberrantly expressed in somatic
embryonic tissues [34]. It is therefore tempting to suggest that the
aberrant transcription in somatic tissues of genes that are normally
expressed in germ cells may contribute to the phenotypic variability
observed in ICF syndrome.
Incomplete phenotype of an ICF patient
One of the analyzed patients showed an incomplete ICF
phenotype (he had neither immunodeficiency, nor the facial
anomalies that are typical of ICF patients) and suffered from
severe obesity. His karyotype contained multibranched and
rearranged chromosomes and, at the molecular level, he was
homozygous for a missense mutation resulting in an aminoacid
change in the region encoding the catalytic domain of the
DNMT3B protein. Loss of DNA methylation was less pronounced
than in the other patients and was never associated with activation
of expression. It is likely that this previously unreported missense
mutation slightly affected the methylation activity of the
DNMT3B protein, resulting in genome instability and a less
pronounced DNA hypomethylation, without producing the
classical ICF phenotype. Other ICF patients having a similar
incomplete phenotype may be under-diagnosed.
To conclude, the striking loss of DNA methylation in
heterochromatic genes, together with their variable pattern of
aberrant expression and the clinical features of the patients
involving numerous systems, make ICF syndrome an ideal model
Heterochromatic Genes Escape Silencing in ICF
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pathological consequences.
Materials and Methods
Patients and controls
Patients and controls used in this study are listed in Table 1.
This study was performed on DNA and RNA extracted from
human lymphoblast cell lines and peripheral blood in the context
of routine molecular diagnostic service. Prof. Andre ´ Megarbane ´
received approval from the Institutional Review Board of the Saint
Joseph University. Written informed consent to genetic testing was
obtained from adult probands or parents in the case of minors
after explanation of the nature and its possible implications to the
patient and his family.
Three lymphoblast cell lines (ICF5, N10 and N11) were
purchased at the Coriell Cell Repositories. The lymphoblast cell
line ICF4 was established at the Genethon laboratory (Evry,
France). Lymphoblast cell lines ICF1, ICF2, ICF3 and N9 were
kindly provided by Dr. Marie-Genevieve Mattei (INSERM UMR
910, Marseille, France).
DNA and RNA extraction
DNA and RNA were extracted from lymphoblast cell lines and
from peripheral blood. DNA was treated with 100 mg/ml
proteinase K at 55uC overnight, then extracted with phenol/
chloroform, ethanol precipitated and treated with 20 mg/ml
RNAse. Total RNA was extracted with Trizol (GIBCO-BRL)
according to the manufacturer recommendations.
Promoter analysis
The chromosome 21 genomic [17] sequence was analyzed with
the ‘‘CpG island searcher’’ software [18] to identify gene-
associated CpG islands. The following criteria were used: CG%
.55% and Observed CpG/Expected CpG .0.65.
DNA methylation analysis
DNA methylation was analyzed by bisulphite genomic sequenc-
ing as described by Frommer et al. [35] and by Grunau et al. [14]
with the following modifications. Three hundred ng of genomic
DNA (extracted from peripheral blood when available, otherwise
from lymphoblast cell lines) were treated with bisulphite and then
purified using the Microcon YM-100 filter device (Millipore) to
separate DNA from bisulphite. PCR amplifications were done in
two consecutive reactions with a set of nested primers. The PCR
program was: 94uC for 2 min; (94uC 1 min, annealing temper-
ature 2 min, 72uC 3 min) for 5 cycles; (94uC 30 sec, annealing
temperature 2 min, 72uC 1 min 30 sec) for 24 cycles; 72uC
10 min. Specific primers and annealing temperatures for each
gene are listed in Table S1. The PCR products were purified on a
low melting agarose gel using the QIAquick gel extraction kit
(Qiagen), cloned into a pGEM-T-Easy (Promega) vector and
transformed into E. Coli JM109 (Promega) cells. Ten colonies per
gene per individual were sequenced with T7 and/or SP6 universal
primers using a DYEnamic ET Terminator Cycle Sequencing kit
(Amersham). The obtained sequences were aligned with the
genomic sequence using the GAP4 computer package [36].
Methylation patterns were analyzed with the MethTools software
[37]. DNA methylation of BAGE genes was also analyzed by
COBRA as previously described [14]. Briefly, using bisulphate
treated genomic DNA, we amplified simultaneously 12 BAGE loci
in a single PCR. The obtained product was digested with MboI
and with HphI in two independent assays and methylation patterns
were analyzed as previously described [14].
Expression analysis
Standard PCR-Two mg of total RNA (extracted from peripheral
blood when available, otherwise from lymphoblast cell lines) were
reverse transcribed using the Omniscript kit (Qiagen) according to
the manufacturer protocol. Reversed DNA was resuspended in
50 ml of 10 mM Tris. One ml of cDNAs was used for PCR and
10 ml of the reaction were analyzed in ethidium bromide-stained
agarose gel. The PCR program was: 94uC 2 min; (94uC 30 sec,
68uC 2 min, 72uC 2 min) for 5 cycles; (94uC 30 sec, annealing
temperature 30 sec; 72uC 2 min) for 25 cycles. Specific primers
used for expression analysis are listed in Table S2. The
housekeeping GAPDH gene was used as control.
TPTE and POTE RT-PCR products were purified on a low
melting agarose gel using the QIAquick gel extraction kit (Qiagen),
cloned into a pGEM-T-Easy (Promega) vector, and transformed
into E. Coli JM109 (Promega) cells. Twelve colonies were
sequenced with the T7 universal primer using a DYEnamic ET
Terminator Cycle Sequencing kit (Amersham).
Real-Time PCR- Two mg of total RNA were reverse transcribed
using the QuantiTect Reverse Transcription kit (#205311
Qiagen) according to the manufacturer protocol. Reversed DNA
was purified using the Qiaquick (#28704 Qiagen). Expression was
quantified using a MyIQ PCR Biorad thermal cycler and the
QPCR Rox-&Go Green kit (#EPQON480 MP Biomedicals).
PCR reactions were done in 25-ml final volume containing
400 nM of each primer and 1 ml of each template DNA
(equivalent to 33 ng of RNA). PCR conditions were the following:
95uC for 15 min, followed by 50 cycles of (95uC3 0s ,6 0 uC3 0s
and 72uC 1 min). We used the housekeeping ABL gene to
normalize cDNA amounts. Primers are listed in Table S2. Each
analysis was done in triplicate and assay efficiencies were
calculated using cDNA dilution series. To calculate gene
expression we used the relative standard curve method.
Chromatin Immunoprecipitation
ChIP experiments were done in 2–3 biological replicates as
previously described [15]. Antibodies were purchased from
Upstate (Millipore): anti-trimethylated H3K9 (#07-442), anti-
monomethylated H3K27 (#07-448), anti-hyperacetylated histone
H4 (penta) (#06-946), and anti-acetylated H3K9 (#07-352).
Real-Time PCR was done in a MyIQ PCR thermal cycler
(Biorad) using the QPCR Rox-&Go Green kit (#EPQON480 MP
Biomedicals). To amplify genomic DNA we designed primers
located in the 3’ end of the CpG islands (Table S2). The
euchromatic GAPDH locus and a heterochromatic STS (JB 10)
served as references to normalize the amount of precipitated DNA
(their primers are given in Table S2). For a detailed description of
normalization see [15]. Briefly, ratios of precipitated DNA in each
gene to that in the reference sequence (either GAPDH or STS
JB10) were calculated as follows: enrichment factor = [ng
GENE(B)/ng GAPDH(B)]/[ng GENE(I)/ng GAPDH(I)] with (B)
for antibody bound and (I) for input. The unbound fraction of
mock-treated chromatin (i.e. precipitation in parallel with the
other ChIP but without antibody) was considered as input. DNA
immunoprecipitated with anti-trimethylated H3K9 and anti-
monomethylated H3K27 was normalized with STS (JB 10);
DNA immunoprecipitated with anti-hyperacetylated histone H4
(penta) and anti-acetylated H3K9 was normalized with GAPDH.
Statistical analysis
The analysis of the methylation was performed for each gene
using x
2 tests at three different levels. First, we checked the
homogeneity of the methylation pattern between the cells of each
individual on the 2 (5mCpG/CpG) x number of cells contingency
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homogeneous methylation pattern. Thus, the data corresponding
to each individual were pooled, leading to the methylation
frequencies for each individual gathered in Table 2. Then, we
tested the homogeneity of the ICF patients and that of the healthy
controls. The ICF group was always very heterogeneous, whereas
the healthy controls showed much more similarity. We neverthe-
less pooled the data of all ICF patients on one side, and that of all
controls on the other side, in order to establish the significance of
the methylation difference between ICF and controls, using a x
2
test on the corresponding 262 contingency table (one degree of
freedom). The p-values corresponding to this final test are given in
Table 2, as well as the overall methylation frequencies for each
group (control and ICF). The significance of the difference
between chromatin changes in ICF versus controls was tested
separately for each gene and for each histone modification using
Wilcoxon’s non-parametric rank sum test.
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